Derek Chan, MD
Alldermis Dermatology
In-Person Visits
Dermatology
Locations + Appointments
In-Person | $250
About Derek Chan, MD
Derek V. Chan, MD, PhD, FAAD
Dr. Chan received his A.B. with honors from Harvard University. He was a biochemical sciences concentrator, and he later completed a joint M.D. and Ph.D. degree at Boston University. His Ph.D. thesis involved the generation of novel therapeutic antibodies for the treatment of certain cancers, including melanomas.
Dr. Chan completed his internship in medicine at Case Western Reserve University and his residency in dermatology at Ohio State University. While at Case Western Reserve University, he completed an NIH-funded T32-funded training grant under the mentorship of Kevin Cooper, MD and was a co-principle investigator on an arm of a NIH-funded project grant that he developed and wrote which focused on programmed cell mediated death and apoptosis. He also enrolled patients in and helped to complete a clinical trial investigating the safety and efficacy of a new treatment for cutaneous T cell lymphoma.
As a fellow of the American Academy of Dermatology and a dermatologist certified by the American Board of Dermatology, Dr. Chan has expertise in both adult medical and cosmetic dermatology. While Dr. Chan can help care for many medical dermatological issues in a private setting, from acne to warts, eczema, and bullous diseases, his medical niche interests include psoriasis, cutaneous lymphomas, pigmented lesions, and hair disorders. Cosmetically, Dr. Chan has expertise in the use of lasers and other procedures for the removal of vascular lesions, scar reduction, fat reduction, and unwanted skin lesions. He is skilled in the use of neurotoxins (e.g. Dysport and Botox), fillers (e.g. Restylane), skin peels, and can help patients with wrinkle reduction and skin rejuvenation.
Dr. Chan has previously served as an ad hoc reviewer for Archives of Dermatology (now JAMA Dermatology) and Clinical Cancer Research. He has spoken at several national and international meetings and has published in several key peer-reviewed journals, including JAMA Dermatology and the Journal of the American Academy of Dermatology. Dr. Chan has also been featured in mass media print and online publications, including Bustle, Prevention.com, and the Daily Mail.
*Patents *
Cooper, KD; McCormick, TS; Somani, A; Sugiyama, H; Chan, DV. “Production of Monoclonal Antibodies specific to LRRC32 also known as glycoprotein A repetitions predominant (GARP).” Filed as an update to USPTO Application #20080279834. Status: Licensed to Becton Dickenson, Millipore, and BioLegend.
*PUBLICATIONS*
*Chan DV*; Kartono F; Ziegler R; Abdulwahab N; DiPaola N; Flynn J; Wong HK. Absence of HLA-DR1 positivity in 2 familial cases of frontal fibrosing alopecia. *J Am Acad Dermatol*. 2014 Nov;71(5):e208-10. doi: 10.1016/j.jaad.2014.05.064. Epub 2014 Oct 15. PubMed PMID: 25437995.
Kaffenberger BH; Lee GL; Tyler K; *Chan DV*; Jarjour W; Ariza ME; Williams MV; Wong HK. Current and potential immune therapies and vaccines in the management of psoriasis. *Hum Vaccin Immunother*. 2014 Apr;10(4):876-86. Epub 2014 Feb 3. PubMed PMID: 24492530.
*Chan DV*; Gibson HM; Aufiero BM; Wilson AJ; Hafner MS; Mi QS; Wong HK. Differential CTLA-4 expression in human CD4+ versus CD8+ T cells is associated with increased NFAT1 and inhibition of CD4+ proliferation. Genes Immun. 2014 Jan;15(1):25-32. doi: 10.1038/gene.2013.57. Epub 2013 Oct 31. PubMed PMID: 24173147; PubMed Central PMCID: PMC4284071.
*Chan, DV;* Wong, HK. “Molecular Genetics of Cutaneous Lymphomas.” *Cutaneous Lymphoma*. Ch. 18. Ed. Hall & Hall. May 31, 2012.
*Chan, DV*; Sharma, R; Ju, CY; Roffler, SR; Ju, ST. A recombinant scFv-FasLext as a targeting cytotoxic agent against human Jurkat-Ras cancer. J Biomed Sci. 2013 Mar 5;20:16. doi: 10.1186/1423-0127-20-16. PubMed PMID: 23497165; PubMed Central PMCID: PMC3599744.
*Chan, DV*; Szabo, D; Frederickson, J; Ziegler, R; Kartono, F; Porcu, PG; Wong, HK. “Combination Romidepsin and PUVA Therapy in a Case of Refractory Advanced Stage CTCL.” International Investigative Dermatology Meeting 2013, Edinburgh, UK, May, 2013. *J Invest Dermatol*. 133: S159-S190; doi:10.1038/jid.2013.102 [abstract]
Gibson, HM; Mishra, A;* Chan, DV*; Hake, TS; Porcu, P; Wong, HK. Impaired proteasome function activates GATA3 in T cells and upregulates CTLA-4: relevance for Sézary syndrome*. J Invest Dermatol*. 2013 Jan;133(1):249-57. doi: 10.1038/jid.2012.265. Epub 2012 Sep 6. PubMed PMID: 22951729.
*Chan, DV*; Hake, TS; Kartono, FK; Porcu, PG; Wong, HK. “Identification of genes to reliably differentiate mycosis fungoides from psoriasis.” Society For Investigative Dermatology Annual Meeting, Raleigh, NC, May, 2012. *J Invest Dermatol.* 132:S149-S173, 2012; doi:10.1038/jid.2012.92 [abstract]
Apisarnthanarax N; Wood GS; Stevens SR; Carlson S; *Chan DV*; Liu L; Szabo SK; Fu P; Gilliam AC; Gerson SL; Remick SC; Cooper KD. Phase I clinical trial of O6-benzylguanine and topical carmustine in the treatment of cutaneous T-cell lymphoma, mycosis fungoides type. *Arch Dermatol*. 2012 May;148(5):613-20. doi:10.1001/archdermatol.2011.2797. PubMed PMID: 22250189
*Chan DV*, Aneja S, Honda K, Carlson S, Yao M, Katcher J, Cooper KD. Radiation therapy in the management of unilesional primary cutaneous T-cell lymphomas. *Br J Dermatol.* 2011 Nov 7. doi: 10.1111/j.1365-2133.2011.10728.x. [Epub ahead of print] PubMed PMID: 22059744.
*Chan DV*, Staidle J, Tamburro J, Mostow E. Rapid cutaneous dissemination of persistently agminated lymphomatoid papulosis in a 9-year-old boy. *Arch Dermatol*.2011 Nov;147(11):1340-2. PubMed PMID: 22106136.
*Chan, DV*; Olack, SB; Carlson, S; Bahner, J; Mostow, E. “Evidence Based Diagnosis of CTCL.” *Evidence Based Dermatology. *Second Edition. Ed. Maibach & Gorouhi. October, 2011.
*Chan, DV*; Somani, AK; Young, AB; Massari, JV; Ohtola, J; Sugiyama, H; Garaczi, E; Babineau, D; Cooper, KD; McCormick; TS. “Signal peptide cleavage is essential for surface expression of leucine rich repeat containing 32/glycoprotein A repetitions predominant (LRRC32/GARP), a regulatory T cell surface protein.” *BMC Biochem*. 2011 May 26;12:27. PubMed PMID: 21615933; PubMed Central PMCID: PMC3127830.
*Chan, DV*; Aneja, S; Honda, L; and Cooper, KD. “CD45RO loss in histopathological specimens of lymphomatoid papulosis. Society For Investigative Dermatology Annual Meeting, Phoenix, AZ, May, 2011. *J Invest Dermatol*. 131(S1):S1-S141, 2011 [abstract]
*Chan, DV*; Summers, P; Tuttle, M; Cooper, KD; Cooper, B; Koon, H; Honda, K. “Anaplastic Lymphoma Kinase Expression in a Recurrent Primary Cutaneous Anaplastic Large Cell Lymphoma with Eventual Systemic Involvement.” Journal of the American Academy of Dermatology. 2011 Sep;65(3):671-3. DOI: 10.1016/j.jaad.2010.06.016. PubMed PMID: 21839333; PubMed Central PMCID: PMC3156415.
Chan, DV; A Somani; A Young; J Massari; E Garaczi; H Sugiyama; K Cooper; & T McCormick. “Functional and Phenotypic Characterization of LRRC32+ and LRRC32- Regulatory T Cells.” *Journal of Investigative Dermatology*. 129(S1):S1-S172, 2009 [abstract]
*Chan, DV. **Generation and Characterization of Engineered Proteins Containing Single Chain Antibodies Fused With the Fas-Binding Portion of Fas Ligand*. Boston University, Boston, MA, 2005 [dissertation]
Jodo, S; Kung, JT; Xiao S;* Chan, DV*; Kobayashi, S; Tateno, M; Lafyatis, R; & Ju, S-T. “Anti-CD95-induced lethality requires radioresistant FcgRII+ cells. A novel mechanism for fulminant hepatic failure.” *J Biol Chem*. 278(9):7553-7, 2003. Epub 2002 Dec 10. PubMed PMID: 12477718.
Jodo, S; Hohlbaum, AM;* Chan, D*; Strehlow, D; Sherr, DH; Marshak-Rothstein, A; & Ju, S-T. “CD95 (Fas) ligand-expressing vesicles display antibody-mediated, FcR-dependent enhancement of cytotoxicity.” *Journal of Immunology*. 165(10):5487-94, 2000. PubMed PMID: 11067901.
*Chan, DV. **Alcoholism and Biases in Alcohol Abuse Screening.* Boston University, Boston, MA, 1999 [thesis]
*Chan, DV*; Auchincloss, H*.* “Human Anti-Pig Cell-Mediated Rejection.” *Xenotransplantation*. 3:158-165, 1996. DOI: 10.1111/j.1399-3089.1996.tb00133.x
*Chan, DV*; Auchincloss, H. “Human Anti-Pig Cell-Mediated Cytotoxicity In Vitro May Have As Many As Three Components.” *Third International Congress for Xenotransplantation Abstracts*. 1995 [abstract]
*MEDIA RESOURCE EDUCATIONAL MATERIALS/RECENT POPULAR ARTICLES*
https://www.bustle.com/articles/182148-7-weird-products-to-use-in-the-shower-according-to-dermatologists
https://www.dailymail.co.uk/health/article-3791398/Are-showering-wrong-Dermatologist-reveals-common-mistakes-make-scrub-right-way.html
https://www.prevention.com/beauty/a20502886/21-crazy-things-your-dermatologist-has-seen/
Dr. Chan received his A.B. with honors from Harvard University. He was a biochemical sciences concentrator, and he later completed a joint M.D. and Ph.D. degree at Boston University. His Ph.D. thesis involved the generation of novel therapeutic antibodies for the treatment of certain cancers, including melanomas.
Dr. Chan completed his internship in medicine at Case Western Reserve University and his residency in dermatology at Ohio State University. While at Case Western Reserve University, he completed an NIH-funded T32-funded training grant under the mentorship of Kevin Cooper, MD and was a co-principle investigator on an arm of a NIH-funded project grant that he developed and wrote which focused on programmed cell mediated death and apoptosis. He also enrolled patients in and helped to complete a clinical trial investigating the safety and efficacy of a new treatment for cutaneous T cell lymphoma.
As a fellow of the American Academy of Dermatology and a dermatologist certified by the American Board of Dermatology, Dr. Chan has expertise in both adult medical and cosmetic dermatology. While Dr. Chan can help care for many medical dermatological issues in a private setting, from acne to warts, eczema, and bullous diseases, his medical niche interests include psoriasis, cutaneous lymphomas, pigmented lesions, and hair disorders. Cosmetically, Dr. Chan has expertise in the use of lasers and other procedures for the removal of vascular lesions, scar reduction, fat reduction, and unwanted skin lesions. He is skilled in the use of neurotoxins (e.g. Dysport and Botox), fillers (e.g. Restylane), skin peels, and can help patients with wrinkle reduction and skin rejuvenation.
Dr. Chan has previously served as an ad hoc reviewer for Archives of Dermatology (now JAMA Dermatology) and Clinical Cancer Research. He has spoken at several national and international meetings and has published in several key peer-reviewed journals, including JAMA Dermatology and the Journal of the American Academy of Dermatology. Dr. Chan has also been featured in mass media print and online publications, including Bustle, Prevention.com, and the Daily Mail.
*Patents *
Cooper, KD; McCormick, TS; Somani, A; Sugiyama, H; Chan, DV. “Production of Monoclonal Antibodies specific to LRRC32 also known as glycoprotein A repetitions predominant (GARP).” Filed as an update to USPTO Application #20080279834. Status: Licensed to Becton Dickenson, Millipore, and BioLegend.
*PUBLICATIONS*
*Chan DV*; Kartono F; Ziegler R; Abdulwahab N; DiPaola N; Flynn J; Wong HK. Absence of HLA-DR1 positivity in 2 familial cases of frontal fibrosing alopecia. *J Am Acad Dermatol*. 2014 Nov;71(5):e208-10. doi: 10.1016/j.jaad.2014.05.064. Epub 2014 Oct 15. PubMed PMID: 25437995.
Kaffenberger BH; Lee GL; Tyler K; *Chan DV*; Jarjour W; Ariza ME; Williams MV; Wong HK. Current and potential immune therapies and vaccines in the management of psoriasis. *Hum Vaccin Immunother*. 2014 Apr;10(4):876-86. Epub 2014 Feb 3. PubMed PMID: 24492530.
*Chan DV*; Gibson HM; Aufiero BM; Wilson AJ; Hafner MS; Mi QS; Wong HK. Differential CTLA-4 expression in human CD4+ versus CD8+ T cells is associated with increased NFAT1 and inhibition of CD4+ proliferation. Genes Immun. 2014 Jan;15(1):25-32. doi: 10.1038/gene.2013.57. Epub 2013 Oct 31. PubMed PMID: 24173147; PubMed Central PMCID: PMC4284071.
*Chan, DV;* Wong, HK. “Molecular Genetics of Cutaneous Lymphomas.” *Cutaneous Lymphoma*. Ch. 18. Ed. Hall & Hall. May 31, 2012.
*Chan, DV*; Sharma, R; Ju, CY; Roffler, SR; Ju, ST. A recombinant scFv-FasLext as a targeting cytotoxic agent against human Jurkat-Ras cancer. J Biomed Sci. 2013 Mar 5;20:16. doi: 10.1186/1423-0127-20-16. PubMed PMID: 23497165; PubMed Central PMCID: PMC3599744.
*Chan, DV*; Szabo, D; Frederickson, J; Ziegler, R; Kartono, F; Porcu, PG; Wong, HK. “Combination Romidepsin and PUVA Therapy in a Case of Refractory Advanced Stage CTCL.” International Investigative Dermatology Meeting 2013, Edinburgh, UK, May, 2013. *J Invest Dermatol*. 133: S159-S190; doi:10.1038/jid.2013.102 [abstract]
Gibson, HM; Mishra, A;* Chan, DV*; Hake, TS; Porcu, P; Wong, HK. Impaired proteasome function activates GATA3 in T cells and upregulates CTLA-4: relevance for Sézary syndrome*. J Invest Dermatol*. 2013 Jan;133(1):249-57. doi: 10.1038/jid.2012.265. Epub 2012 Sep 6. PubMed PMID: 22951729.
*Chan, DV*; Hake, TS; Kartono, FK; Porcu, PG; Wong, HK. “Identification of genes to reliably differentiate mycosis fungoides from psoriasis.” Society For Investigative Dermatology Annual Meeting, Raleigh, NC, May, 2012. *J Invest Dermatol.* 132:S149-S173, 2012; doi:10.1038/jid.2012.92 [abstract]
Apisarnthanarax N; Wood GS; Stevens SR; Carlson S; *Chan DV*; Liu L; Szabo SK; Fu P; Gilliam AC; Gerson SL; Remick SC; Cooper KD. Phase I clinical trial of O6-benzylguanine and topical carmustine in the treatment of cutaneous T-cell lymphoma, mycosis fungoides type. *Arch Dermatol*. 2012 May;148(5):613-20. doi:10.1001/archdermatol.2011.2797. PubMed PMID: 22250189
*Chan DV*, Aneja S, Honda K, Carlson S, Yao M, Katcher J, Cooper KD. Radiation therapy in the management of unilesional primary cutaneous T-cell lymphomas. *Br J Dermatol.* 2011 Nov 7. doi: 10.1111/j.1365-2133.2011.10728.x. [Epub ahead of print] PubMed PMID: 22059744.
*Chan DV*, Staidle J, Tamburro J, Mostow E. Rapid cutaneous dissemination of persistently agminated lymphomatoid papulosis in a 9-year-old boy. *Arch Dermatol*.2011 Nov;147(11):1340-2. PubMed PMID: 22106136.
*Chan, DV*; Olack, SB; Carlson, S; Bahner, J; Mostow, E. “Evidence Based Diagnosis of CTCL.” *Evidence Based Dermatology. *Second Edition. Ed. Maibach & Gorouhi. October, 2011.
*Chan, DV*; Somani, AK; Young, AB; Massari, JV; Ohtola, J; Sugiyama, H; Garaczi, E; Babineau, D; Cooper, KD; McCormick; TS. “Signal peptide cleavage is essential for surface expression of leucine rich repeat containing 32/glycoprotein A repetitions predominant (LRRC32/GARP), a regulatory T cell surface protein.” *BMC Biochem*. 2011 May 26;12:27. PubMed PMID: 21615933; PubMed Central PMCID: PMC3127830.
*Chan, DV*; Aneja, S; Honda, L; and Cooper, KD. “CD45RO loss in histopathological specimens of lymphomatoid papulosis. Society For Investigative Dermatology Annual Meeting, Phoenix, AZ, May, 2011. *J Invest Dermatol*. 131(S1):S1-S141, 2011 [abstract]
*Chan, DV*; Summers, P; Tuttle, M; Cooper, KD; Cooper, B; Koon, H; Honda, K. “Anaplastic Lymphoma Kinase Expression in a Recurrent Primary Cutaneous Anaplastic Large Cell Lymphoma with Eventual Systemic Involvement.” Journal of the American Academy of Dermatology. 2011 Sep;65(3):671-3. DOI: 10.1016/j.jaad.2010.06.016. PubMed PMID: 21839333; PubMed Central PMCID: PMC3156415.
Chan, DV; A Somani; A Young; J Massari; E Garaczi; H Sugiyama; K Cooper; & T McCormick. “Functional and Phenotypic Characterization of LRRC32+ and LRRC32- Regulatory T Cells.” *Journal of Investigative Dermatology*. 129(S1):S1-S172, 2009 [abstract]
*Chan, DV. **Generation and Characterization of Engineered Proteins Containing Single Chain Antibodies Fused With the Fas-Binding Portion of Fas Ligand*. Boston University, Boston, MA, 2005 [dissertation]
Jodo, S; Kung, JT; Xiao S;* Chan, DV*; Kobayashi, S; Tateno, M; Lafyatis, R; & Ju, S-T. “Anti-CD95-induced lethality requires radioresistant FcgRII+ cells. A novel mechanism for fulminant hepatic failure.” *J Biol Chem*. 278(9):7553-7, 2003. Epub 2002 Dec 10. PubMed PMID: 12477718.
Jodo, S; Hohlbaum, AM;* Chan, D*; Strehlow, D; Sherr, DH; Marshak-Rothstein, A; & Ju, S-T. “CD95 (Fas) ligand-expressing vesicles display antibody-mediated, FcR-dependent enhancement of cytotoxicity.” *Journal of Immunology*. 165(10):5487-94, 2000. PubMed PMID: 11067901.
*Chan, DV. **Alcoholism and Biases in Alcohol Abuse Screening.* Boston University, Boston, MA, 1999 [thesis]
*Chan, DV*; Auchincloss, H*.* “Human Anti-Pig Cell-Mediated Rejection.” *Xenotransplantation*. 3:158-165, 1996. DOI: 10.1111/j.1399-3089.1996.tb00133.x
*Chan, DV*; Auchincloss, H. “Human Anti-Pig Cell-Mediated Cytotoxicity In Vitro May Have As Many As Three Components.” *Third International Congress for Xenotransplantation Abstracts*. 1995 [abstract]
*MEDIA RESOURCE EDUCATIONAL MATERIALS/RECENT POPULAR ARTICLES*
https://www.bustle.com/articles/182148-7-weird-products-to-use-in-the-shower-according-to-dermatologists
https://www.dailymail.co.uk/health/article-3791398/Are-showering-wrong-Dermatologist-reveals-common-mistakes-make-scrub-right-way.html
https://www.prevention.com/beauty/a20502886/21-crazy-things-your-dermatologist-has-seen/
Board Certifications
American Board of Dermatology
Locations
Additional Links